CLS

CLS Americas Announces 2nd Order of TRANBERG™ Focal Laser Ablation Accessories Placed by the National Institutes of Health Clinical Center

Retrieved on: 
Tuesday, April 9, 2024
Diagnosis, Temperature, Urology, Prostate cancer, Patient, NIHCC, FLA, NIH, Male, Urinary incontinence, Erectile dysfunction, CLS, Bangladesh Technical Education Board, Medical imaging

LOS ANGELES, April 09, 2024 (GLOBE NEWSWIRE) -- Clinical Laserthermia Systems Americas, Inc. (CLS), a leading provider of office-based, focal laser ablation (FLA) systems for urologists, today announced it has received its second order from the National Institutes of Health Clinical Center (NIHCC) for its TRANBERG™ Thermal Therapy System accessories.

Key Points: 
  • LOS ANGELES, April 09, 2024 (GLOBE NEWSWIRE) -- Clinical Laserthermia Systems Americas, Inc. (CLS), a leading provider of office-based, focal laser ablation (FLA) systems for urologists, today announced it has received its second order from the National Institutes of Health Clinical Center (NIHCC) for its TRANBERG™ Thermal Therapy System accessories.
  • The order falls under the previously announced research collaboration agreement between NIHCC and its parent company, Clinical Laserthermia Systems AB, based in Sweden.
  • “This second order of our TRANBERG Focal Laser Ablation accessories enables our continued collaboration with the NIH to evaluate our TRANBERG laser for image-guided, focal therapies to treat prostate cancer,” said Michael Magnani, President of CLS Americas.
  • It includes a desk-top mobile laser unit, innovative non-cooled laser applicators, tissue temperature probes, and procedure-specific accessories.

CLS Americas Announces ROSE Urology will use TRANBERG Laser to Treat Prostate Cancer Patients with Focal Laser Ablation

Retrieved on: 
Thursday, March 28, 2024
Diagnosis, Temperature, Urology, Prostate cancer, Patient, Cancer, Prostate, FLA, Urinary incontinence, Erectile dysfunction, CLS, FDA, Physician, Medical imaging

LOS ANGELES, March 28, 2024 (GLOBE NEWSWIRE) -- Clinical Laserthermia Systems Americas, Inc. (CLS), a leading provider of office-based, focal laser ablation (FLA) systems for urologists, today announced that ROSE Urology, LLC , located in Vero Beach, Florida, will begin using the TRANBERG™ Thermal Therapy System to treat prostate cancer patients.

Key Points: 
  • LOS ANGELES, March 28, 2024 (GLOBE NEWSWIRE) -- Clinical Laserthermia Systems Americas, Inc. (CLS), a leading provider of office-based, focal laser ablation (FLA) systems for urologists, today announced that ROSE Urology, LLC , located in Vero Beach, Florida, will begin using the TRANBERG™ Thermal Therapy System to treat prostate cancer patients.
  • The system is FDA 510(k) cleared for soft tissue ablation in a urology setting.
  • Operating under CLS's Mobile Services Agreement, CLS will provide its FDA 510(k) cleared TRANBERG Laser, consumable accessories, training, and on-site clinical and technical support to ROSE Urology physicians and staff during procedures.
  • Focal laser ablation of prostate tumors has demonstrated high levels of precision and accuracy with low risk of side effects, such as erectile dysfunction and urinary incontinence.

Synthekine Presents Positive Initial Results from Phase 1a/1b Clinical Trial of α/β Biased IL-2, STK-012, for Treatment of Advanced Solid Tumors

Retrieved on: 
Tuesday, April 9, 2024
Oncology, FDA, Health, Clinical Trials, Pharmaceutical, Biotechnology, Arthralgia, Toxicity, Cell, NSCLC, RECIST, HNSCC, Patient, Diarrhea, Maculopapular rash, Lung cancer, Renal cell carcinoma, Injection site reaction, AACR, Nausea, Lymphocyte, Hypotension, RCC, Transaminase, Poster, Itch, CLS, Capillary leak syndrome, Fatigue, Vomiting, NK, Inc., Pharmaceutical industry

Synthekine Inc ., an engineered cytokine therapeutics company, today announced positive initial results from a Phase 1a/1b clinical trial of its α/β biased IL-2 partial agonist, STK-012, for the treatment of advanced solid tumors.

Key Points: 
  • Synthekine Inc ., an engineered cytokine therapeutics company, today announced positive initial results from a Phase 1a/1b clinical trial of its α/β biased IL-2 partial agonist, STK-012, for the treatment of advanced solid tumors.
  • The data were presented at the American Association for Cancer Research (AACR) Annual Meeting 2024 in San Diego.
  • In the results presented, which included 47 patients treated in Phase 1a dose escalation, STK-012 monotherapy demonstrated a favorable safety, efficacy, pharmacokinetic and pharmacodynamic profile.
  • The poster, titled “Initial results from a Phase 1a/1b study of STK-012, a first-in-class α/β IL-2 receptor biased partial agonist in advanced solid tumors (NCT05098132),” will be presented today at AACR from 9 am to 12:30 pm PT.

Clearside Biomedical Appoints Victor Chong, M.D., MBA as Chief Medical Officer

Retrieved on: 
Monday, March 18, 2024
DAS, Retina, University, Moorfields Eye Hospital, Pathology, Oligonucleotide, Ranibizumab, Data analysis, Partnership, Business, Boehringer Ingelheim, DME, Patient, Pharming, Research, Royal College of Ophthalmologists, Cell biology, Diabetic retinopathy, C3, University College London, MBA, Eye, Johnson & Johnson, Janssen, Drug development, John Radcliffe Hospital, AMD, CLS, University of Oxford, Royal college, Geographic atrophy, Stargardt disease, DMI, Pharmaceutical industry

ALPHARETTA, Ga., March 18, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today that Victor Chong, M.D., MBA was appointed Chief Medical Officer on March 14, 2024.

Key Points: 
  • ALPHARETTA, Ga., March 18, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today that Victor Chong, M.D., MBA was appointed Chief Medical Officer on March 14, 2024.
  • George Lasezkay, Pharm.D., J.D., President and Chief Executive Officer of Clearside, commented, “Victor is a well-known and well-respected retinal clinician and scientist, who is a strategically focused and visionary leader.
  • We are delighted to have him join the Clearside team.
  • “With the upcoming ODYSSEY data and extensive partnership portfolio, this is an exciting time to join Clearside.

Clearside Biomedical Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

Retrieved on: 
Tuesday, March 12, 2024
Patient, G&A, BioCryst Pharmaceuticals, Eye, Drug delivery, Clinical trial, AAO, Extension, Webcast, Pharming, CPT, Safety, Disease, SPA, American Academy of Ophthalmology, Compass, Insurance, Diabetic retinopathy, Conference call, Aura, AMD, TKI, CLS, FDA, Administration, Conference, SCS, DME, American Academy, OASIS, Injection, Research and development, Axitinib, Pharmaceutical industry

ALPHARETTA, Ga., March 12, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), today reported financial results for the fourth quarter and year ended December 31, 2023, and provided a corporate update.

Key Points: 
  • License Revenue: License and other revenue for the fourth quarter of 2023 was $6.3 million, compared to $0.3 million for the fourth quarter of 2022.
  • Research and Development (R&D) Expenses: R&D expenses for the fourth quarter of 2023 were $6.3 million, compared to $5.0 million for the fourth quarter of 2022.
  • General and Administrative (G&A) Expenses: G&A expenses for the fourth quarter of 2023 were $2.9 million, compared to $3.2 million for the fourth quarter of 2022.
  • Other Expense: Non-cash interest expense for the fourth quarter of 2023 was $2.3 million, compared to $2.0 million for the fourth quarter of 2022.

Swift Sets Industry Up for Seamless Introduction of CBDCs for Cross-Border Transactions as Interlinking Solution Finds More Use Cases

Retrieved on: 
Monday, March 25, 2024
Carriers and Services, Technology, Professional Services, Payments, Electronic Commerce, Blockchain, Security, Networks, Internet, Fintech, Mobile, Wireless, Deutsche Bank, CLS Group, Automation, Savings bank, Standard Bank, Growth, United Overseas Bank, DVP, Tokenization, ANZ, Westpac, Risk, Sumitomo Mitsui Banking Corporation, Digital asset, Public policy, Intesa Sanpaolo, CBDC, Community business development corporation, Commercial, DTCC, Standard Chartered, DLT, NatWest Group, Ecosystem, HSBC, FX, CLS, DBS, Commercial bank, Cryptocurrency

Swift’s solution has already been shown to enable cross-border transfers and connect CBDCs on different networks with each other, as well as with fiat currencies.

Key Points: 
  • Swift’s solution has already been shown to enable cross-border transfers and connect CBDCs on different networks with each other, as well as with fiat currencies.
  • The second phase of sandbox testing went further, exploring more complex use cases, using Swift’s solution to connect and orchestrate transactions across simulated digital trade and tokenised asset and FX networks, alongside CBDCs for payments.
  • Swift now plans to extend its solution to support a wider range of emerging digital networks in addition to CBDCs, such as platforms for tokenised deposits.
  • This will help to facilitate access and usage of CBDCs in the new complex world of digital payments.

Windstream Wholesale Announces Enhancements of Two Key Routes, Elevating Connectivity from Ashburn to Virginia Beach

Retrieved on: 
Monday, March 18, 2024
Networks, Internet, Technology, Carriers and Services, Telecommunications, DWDM, OTDR, RLS, ICON, FLEX, MTTR, CLS, Marketing

Windstream Wholesale, an optical technology leader in advanced network solutions, today announced the completion of two pivotal route enhancement projects using FLEX DWDM (FLEX) technology, bolstering connectivity across Virginia.

Key Points: 
  • Windstream Wholesale, an optical technology leader in advanced network solutions, today announced the completion of two pivotal route enhancement projects using FLEX DWDM (FLEX) technology, bolstering connectivity across Virginia.
  • The FLEX upgrade extends across Windstream’s ICON network from Ashburn through Richmond, Virginia, and into the Virginia Beach cable landing station (CLS).
  • The route segment from Ashburn to Richmond serves as a vital connection between key data centers while the extension from Richmond to the Virginia Beach subsea CLS opens new avenues for international connectivity.
  • “As technology continues to evolve, so do the demands placed on networks,” added Joe Scattareggia, Windstream Wholesale president.

SF Intra-city Realised Profitability in 2023, Demonstrating High-Quality and Healthy Growth

Retrieved on: 
Tuesday, March 26, 2024
Cloud, Spring Festival, Tea, The Spring Festival, Software as a service, Growth, RMB, KA, Acceleration, Beauty, Acquisition, AI, Meal, Credit, Holiday, SF, Ecosystem, Language, CLS, Pet, Jewellery, Marketing, Ali Baba, CBWK-FM, Retail

HONG KONG, March 26, 2024 /PRNewswire/ -- Hangzhou SF Intra-city Industrial Co., Ltd. ("SF Intra-city" or the "Group"; Stock Code: 9699.HK), the largest third-party on-demand delivery service provider in China, announced its audited annual results for the year ended 31 December 2023 (the "Reporting Period"). During the Reporting Period, the Group achieved satisfactory annual result. SF Intra-city's revenue from continuing operations experienced steady growth, increasing by 21.1% to RMB 12,387.4 million, and the total order volume increased by over 30% year-on-year; gross profit recorded a strong year-on-year growth of 93.5% reaching as high as RMB 794.7 million; gross profit margin substantially increased by 2.4 percentage points to 6.4%. The Group's net profit from the continuing operations was RMB64.9 million, and net profit margin substantially improved to 0.5% year-on-year.

Key Points: 
  • SF Intra-city recorded net cash generated from operating activities of RMB266.3 million for the year of 2023.
  • This can be attributed to our multi-scenario business model leading to a growth of order density and optimization of business structure.
  • In 2023, the revenue from intra-city delivery service for merchants reached RMB 5,219.7 million, representing a year-on-year growth of 12.3%.
  • SF Intra-city rapidly expanded and densified our nationwide delivery network, leading to a growth in business districts and order density.

SF Intra-city maintains steady business growth, set to become first in industry to achieve full-year profitability

Retrieved on: 
Tuesday, March 12, 2024
Growth, Bread, International Women's Day, SF, Drink, CLS, Central business district, Supermarket, Flower

The profit turnaround achieved by SF Intra-city was mainly attributable to healthy and steady revenue growth, an increase in order density and further enhancement of network economies of scale.

Key Points: 
  • The profit turnaround achieved by SF Intra-city was mainly attributable to healthy and steady revenue growth, an increase in order density and further enhancement of network economies of scale.
  • Meanwhile, the effective business strategy of the Group has pursued healthy and high-quality development, continuous optimisation of the business and customer structure, and increasing contribution to revenue by premium customers and profitable business lines.
  • Through the relentless efforts of all employees, the group has become the first to achieve profitability in the logistics and same-day delivery industry.
  • The company will fully utilize its own advantages to capture high-quality growth opportunities and enhance profitability while steadily creating greater value for shareholders.

Celestica Files Form 20-F

Retrieved on: 
Monday, March 11, 2024
TSX, CLS, Form, Annual report

The annual report on Form 20-F can be accessed on the company's website at www.celestica.com in the Investor Relations section.

Key Points: 
  • The annual report on Form 20-F can be accessed on the company's website at www.celestica.com in the Investor Relations section.
  • The Form 20-F can also be viewed at www.sedarplus.com and at www.sec.gov .
  • The company's shareholders are entitled to receive copies of the Form 20-F free of charge.
  • Shareholders who have already requested a copy of the Form 20-F will receive this document in the mail.